Mucosis creates SAB
This article was originally published in Scrip
Executive Summary
Dutch biotech company Mucosis, which is developing mucosal vaccines, has formed a new scientific advisory board. The members are: Dr Jiri Mestecky, who is with the department of microbiology and medicine at the University of Alabama; Dr Willem van Eden from the department of infectious diseases and immunology of the veterinary faculty at Utrecht University in the Netherlands; and Dr Peter Openshaw, a professor of experimental medicine and director of the Centre for Respiratory Infection at the National Heath and Lung Institute at Imperial College, London.